FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 332:1192-1197 May 4, 1995 Number 18 Next

	Full Text PDF Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article Related Article by Bihari, D. J. PubMed Citation

ABSTRACT

Background Previous studies have suggested that the transjugular placement of an intrahepatic stent to establish a portosystemic shunt is an effective treatment of uncomplicated ascites accompanying variceal bleeding. We studied the stent shunt for use in patients with liver cirrhosis and ascites refractory to medical treatment.

Methods Fifty of 62 consecutive patients with cirrhosis and refractory ascites were treated with the stent shunt — an expandable stent of metallic mesh placed between a major branch of the portal vein and one of the hepatic veins. Patients were followed for a mean (±SD) of 426±333 days.

Results The stent shunt was successfully placed in all patients and reduced the pressure gradient between the portal vein and the inferior vena cava by an average of 63 percent. Thirty-seven patients (74 percent) had complete responses (total remission of ascites within three months), and nine patients (18 percent) had partial responses. Four patients did not respond, including two who died within two weeks of shunt placement. After the procedure, 25 patients had hepatic encephalopathy, as compared with 20 patients before the procedure; although encephalopathy improved in 3 patients, new encephalopathy developed in 8 patients. In the 28 of the 33 patients followed for more than six months who were evaluated, the mean serum creatinine concentration was 1.5±0.09 mg per deciliter (133±8 µmol per liter) before placement of the stent shunt, 1.5±1.6 mg per deciliter (133±141 µmol per liter) one week after the procedure, and 0.9±0.3 mg per deciliter (80±27 µmol per liter) after six months (P = 0.008 for the comparison of concentrations before and six months after the procedure). Renal function did not improve in the six patients with organic kidney disease. Procedure-related complications developed in 16 patients. During follow-up, an additional 29 patients died — 10 of progressive liver disease and 19 of other causes. Survival for at least one year was associated with a patient's being under 60 years of age, having a serum bilirubin level before placement of the stent shunt of less than 1.3 mg per deciliter (22 µmol per liter), and having a complete response.

Conclusions Our findings in an uncontrolled prospective study suggest that the transjugular intrahepatic portosystemic stent–shunt procedure was an effective treatment for many patients with liver cirrhosis and refractory ascites, but mortality from underlying diseases was substantial.

Source Information

From the Departments of Medicine (A.O., M.R., K.H., P.D., V.S., M.H., H.E.B.) and Radiology (K.-H.H., M.L.), Albert Ludwig University School of Medicine, Freiburg, Germany.

Address reprint requests to Dr. Rössle at the Medizinische Universitätsklinik II, Hugstetterstr. 55, 79106 Freiburg, Germany.

Full Text of this Article

Related Letters:

Transjugular Intrahepatic Portosystemic Stent Shunt for Ascites
Fabrega A. J., Martin M., Ochs A., Haag K., Rössle M.
Extract | Full Text  
N Engl J Med 1995; 333:878-879, Sep 28, 1995. Correspondence

This article has been cited by other articles:

• Moore, K P, Aithal, G P (2006). Guidelines on the management of ascites in cirrhosis. Gut 55: vi1-vi12 [Full Text]  
• Wadei, H. M., Mai, M. L., Ahsan, N., Gonwa, T. A. (2006). Hepatorenal Syndrome: Pathophysiology and Management. CJASN 1: 1066-1079 [Full Text]  
• Yoon, C. J., Chung, J. W., Park, J. H. (2005). Transjugular Intrahepatic Portosystemic Shunt for Acute Variceal Bleeding in Patients with Viral Liver Cirrhosis: Predictors of Early Mortality. Am. J. Roentgenol. 185: 885-889 [Abstract] [Full Text]  
• Vignali, C., Bargellini, I., Grosso, M., Passalacqua, G., Maglione, F., Pedrazzini, F., Filauri, P., Niola, R., Cioni, R., Petruzzi, P. (2005). TIPS with Expanded Polytetrafluoroethylene-Covered Stent: Results of an Italian Multicenter Study. Am. J. Roentgenol. 185: 472-480 [Abstract] [Full Text]  
• ter Borg, P. C. J., Hollemans, M., van Buuren, H. R., Vleggaar, F. P., Groeneweg, M., Hop, W. C. J., Lameris, J. S. (2004). Transjugular Intrahepatic Portosystemic Shunts: Long-term Patency and Clinical Results in a Patient Cohort Observed for 3-9 Years. Radiology 231: 537-545 [Abstract] [Full Text]  
• Gines, P., Cardenas, A., Arroyo, V., Rodes, J. (2004). Management of Cirrhosis and Ascites. NEJM 350: 1646-1654 [Full Text]  
• Yamagami, T., Kato, T., Iida, S., Tanaka, O., Nishimura, T. (2003). Change in the Hemodynamics of the Portal Venous System After Retrograde Transvenous Balloon Occlusion of a Gastrorenal Shunt. Am. J. Roentgenol. 181: 1011-1015 [Abstract] [Full Text]  
• Angermayr, B, Cejna, M, Karnel, F, Gschwantler, M, Koenig, F, Pidlich, J, Mendel, H, Pichler, L, Wichlas, M, Kreil, A, Schmid, M, Ferlitsch, A, Lipinski, E, Brunner, H, Lammer, J, Ferenci, P, Gangl, A, Peck-Radosavljevic, M (2003). Child-Pugh versus MELD score in predicting survival in patients undergoing transjugular intrahepatic portosystemic shunt. Gut 52: 879-885 [Abstract] [Full Text]  
• Bellis, L, Moitinho, E, Abraldes, J G, Graupera, M, Garcia-Pagan, J C, Rodes, J, Bosch, J (2003). Acute propranolol administration effectively decreases portal pressure in patients with TIPS dysfunction. Gut 52: 130-133 [Abstract] [Full Text]  
• Suzuki, H., Stanley, A.J. (2001). Current management and novel therapeutic strategies for refractory ascites and hepatorenal syndrome. QJM 94: 293-300 [Abstract] [Full Text]  
• Brensing, K A, Textor, J, Perz, J, Schiedermaier, P, Raab, P, Strunk, H, Klehr, H U, Kramer, H J, Spengler, U, Schild, H, Sauerbruch, T (2000). Long term outcome after transjugular intrahepatic portosystemic stent-shunt in non-transplant cirrhotics with hepatorenal syndrome: a phase II study. Gut 47: 288-295 [Abstract] [Full Text]  
• Rossle, M., Ochs, A., Gulberg, V., Siegerstetter, V., Holl, J., Deibert, P., Olschewski, M., Reiser, M., Gerbes, A. L. (2000). A Comparison of Paracentesis and Transjugular Intrahepatic Portosystemic Shunting in Patients with Ascites. NEJM 342: 1701-1707 [Abstract] [Full Text]  
• Plauth, M, Roske, A-E, Romaniuk, P, Roth, E, Ziebig, R, Lochs, H (2000). Post-feeding hyperammonaemia in patients with transjugular intrahepatic portosystemic shunt and liver cirrhosis: role of small intestinal ammonia release and route of nutrient administration. Gut 46: 849-855 [Abstract] [Full Text]  
• JALAN, R, LUI, H F, REDHEAD, D N, HAYES, P C (2000). TIPSS 10 years on. Gut 46: 578-581 [Full Text]  
• Koike, T., Araki, S., Minakami, H., Ogawa, S., Sayama, M., Shibahara, H., Sato, I. (2000). Clinical efficacy of peritoneovenous shunting for the treatment of severe ovarian hyperstimulation syndrome. Hum Reprod 15: 113-117 [Abstract] [Full Text]  
• GINÈS, P., ARROYO, V. (1999). Hepatorenal Syndrome. J. Am. Soc. Nephrol. 10: 1833-1839 [Full Text]  
• Fabrega, A. J., Martin, M., Ochs, A., Haag, K., Rossle, M. (1995). Transjugular Intrahepatic Portosystemic Stent Shunt for Ascites. NEJM 333: 878-879 [Full Text]  
• (1995). TIPS FOR REFRACTORY ASCITES. JWatch General 1995: 2-2 [Full Text]